ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PRLD / financials
ENTA (20) ARCT (25) IRD (23) BNTC (30) ⌘ Pro Terminal →

Prelude Therapeutics Incorporated (PRLD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.84 -1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.83

Prelude Therapeutics Incorporated (PRLD) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $309.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRLD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.84 (-1.03% 1D, market cap $309.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRLD ranks #679 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRLD compare to ENTA and ARCT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while PRLD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRLD?
▼

Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.83 (-0.38%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (7)SEC (11)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$7 Bull$3 Base$3 Bear
📬 FREE PRLD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRLD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY PRLD SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
25
Grade E$3.56-0.8% Next Q
Q2 (-2Q)
28
Grade E$3.53+9.9% Next Q
Q3 (-1Q)
30
Grade E$3.88-1% Next Q
Current
33
Grade E$3.84-8.9% Hist 90D α
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRLD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRLD currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.35) and Max Pain ($4.03) forces dealer call-delta covering toward $7.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRLD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PRLD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$12.1MGross Profit $6.3M (52%)Cost of Sales $5.8MOp Profit $0 (0%)OpEx (R&D/SG&A) $6.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $370.4M
FY24
Rev $7.0M
FY25
Rev $12.1M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$12.1M52%-80%-$99.5M-$56.4M-45%
FY 2024$7.0M52%-80%-$127.2M-$103.7M-45%
FY 2023$370.4M52%-35.7%-$121.8M-$107.1M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRLD)

  • ✓Walkthrough of PRLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.99%📐 HORIZONTAL RANGE
2026-11-03O $4.10H $4.10L $3.84C $3.84VOL 218.1K
RES: $7.86SUP: $3.06SMA50: $4.35SMA200: $4.03
$7.16$5.79$4.43$3.06$1.70RES $7.86SUP $3.06$3.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRLD Butterfly Map → + Track PRLD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +73.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRLD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRLD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRLD)

Health Care Rank #679 of 1015 ⚔️ ENTA vs PRLD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRLD vs. ENTA, ARCT, IRD, BNTC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Prelude Therapeutics Incorporated (PRLD) ranks #679 by composite RQD confidence (33/100, grade E) and #511 by equity capitalization ($309.6M). Within this direct 5-issuer industry benchmark cohort, PRLD leads on earnings valuation at N/A trailing P/E, while PRLD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PRLD currently leads its immediate peer cohort in composite quantitative strength at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRLD ACTIVE
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -1.03% $309.6M Benchmark Subject
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-prld →
ARCT
Arcturus Therapeutics Holdings Inc.
E 25/100 — — -35.0% -13.96% $313.5M /arct-vs-prld →
IRD
Opus Genetics Inc.
E 23/100 — — -35.0% +0.82% $305.3M /ird-vs-prld →
BNTC
Benitec Biopharma Inc.
E 30/100 — — -35.0% -2.86% $304.9M /bntc-vs-prld →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001678660 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported GAAP revenue of $12.1M (+73.4% vs. FY2024 revenue of $7.0M , and -96.7% cumulative change since FY2023) , GAAP net income of -$99.5M, operating cash flow of -$56.3M, and free cash flow of -$56.4M (+45.6% YoY). On the balance sheet, PRLD closed FY2025 with $141.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $12.1M -$99.5M -$56.3M -$56.4M $141.3M —
FY2024 (FY) 2024-12-31 $7.0M -$127.2M -$102.9M -$103.7M $175.5M —
FY2023 (FY) 2023-12-31 $370.4M -$121.8M -$107.1M -$107.1M — —

3. PRLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.84 (-1.03% 1D, market cap $309.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRLD ranks #679 in composite RQD confidence.

How does PRLD compare to ENTA and ARCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENTA (Enanta Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $311.9M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while PRLD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRLD?

Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRLD trading relative to its 50-day, 200-day, and 52-week technical levels?

PRLD last traded at $3.84 (-1.03% on volume of 216,177 shares), positioning the stock -11.72% below its 50-day simple moving average ($4.35) and -4.71% below its 200-day simple moving average ($4.03). Across its 52-week range of $1.17 to $6.83, PRLD sits at the 47.2% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.36 to $4.32).

Direct Sub-Reports: PRLD RQD Cockpit PRLD 12M Forecast PRLD Earnings & Move PRLD Dividends & DRIP PRLD Insiders & 13F PRLD Whale Options PRLD Profit Sankey PRLD News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

PRLD — Prelude Therapeutics Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Prelude Therapeutics Incorporated (PRLD) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.84 (-1.03% 1D, market capitalization $309.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -17.23%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Prelude Therapeutics Incorporated (PRLD) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.3B. Reported revenue of $12.1M for FY 2025 is shown in the SEC financials, but its composition is not detailed in source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported $12.1M in annual revenue (up from $7.0M in FY2024, +73.4% YoY) and -$99.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($370.4M revenue, -$121.8M net income) through FY2025, PRLD scaled operating cash flow to -$56.3M and free cash flow to -$56.4M, backed by $141.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.23% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $1.17 – $6.83 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlations beyond the stated beta of 1.

  • Key Question #1: Can PRLD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $12.1M and free cash flow of -$56.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PRLD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRLD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prelude Therapeutics Incorporated (PRLD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRLD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRLD Bull vs. Bear Conversation Board — What's Your Call at $3.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRLD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRLD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.73 (+21.9%)
📌 Pinned Debate

Operating losses narrowed from -$139.7M in FY 2024 to -$104.6M in FY 2025 while cash rose to $35.3M, with a reported Incyte option and

Picked up a starter position in PRLD in my $100K Virtual Cash book at $3.88. Operating losses narrowed from -$139.7M in FY 2024 to -$104.6M in FY 2025 while cash rose to $35.3M, with a reported Incyte option and Lilly deal in the news feed.. Trading inside a $1.17–$6.83 52-week range with -17.23% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — PRLD's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $3.03 (-21.9%)
Spot @ $3.88

ROIC of -35%, FCF yield of -17.23%, and an insider conviction score of 3/20 indicate sustained cash burn and weak insider support.

Careful chasing PRLD at $3.88. ROIC of -35%, FCF yield of -17.23%, and an insider conviction score of 3/20 indicate sustained cash burn and weak insider support.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.03 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%